Genetic Influence of CYP2D6 on Risperidone Metabolism: Pharmacokinetic and Pharmacodynamic Study in a Healthy South Indian Population
Human Psychopharmacology: Clinical and Experimental · 2026-05 · 41 (3)
DOI: 10.1002/hup.70044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 29.04.2026. Verfasst von Ramanujam Narayanan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Risperidone, Antipsychotic Agents. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objective
The CYP2D6*10 allele, which is prevalent in the Indian population, is of particular clinical significance. This study aims to investigate the effect of the CYP2D6*10 allele on the pharmacokinetics of risperidone and its metabolites following single‐dose administration in healthy South Indian volunteers.
Methods
The study was conducted with twenty healthy volunteers who were administered a single 2 mg dose of risperidone. CYP2D6 genotyping was performed using the PCR‐RFLP method. Plasma levels of risperidone (RIS) and its active metabolite 9‐hydroxyrisperidone (9‐OHRIS) were quantified using a UPLC‐DAD system.
Results
Significant differences in pharmacokinetic parameters were observed across the CYP2D6*10 genotypes. For intermediate metabolizers, the C max , AUC 0– t , and T 1/2 were approximately 1.2 times higher, and the metabolic ratio was double compared to normal metabolizers. Notably, the C max of the active moiety was significantly higher in intermediate metabolizers compared to normal metabolizers ( p < 0.05). These findings indicate that CYP2D6 polymorphisms are associated with altered pharmacokinetic profiles of risperidone, with a reduced metabolic activation in individuals carrying the *10 allele.
Conclusion
The results suggest that CYP2D6 genotyping could help inform personalized dosing strategies for risperidone, though further randomized controlled trials are required to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
- Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.
- PSG-Centre for Molecular Medicine and Therapeutics, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
- Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
ORCID-Profile: Ramanujam Narayanan, Susipriya Palanisamy
Zitieren
APA
Narayanan, R., Rahman, H., Palanisamy, S., Ranjithkumar, R., & Muthusamy, S. (2026). Genetic Influence of CYP2D6 on Risperidone Metabolism: Pharmacokinetic and Pharmacodynamic Study in a Healthy South Indian Population. Human Psychopharmacology: Clinical and Experimental, 41(3). https://doi.org/10.1002/hup.70044
Vancouver
Narayanan R, Rahman H, Palanisamy S, Ranjithkumar R, Muthusamy S. Genetic Influence of CYP2D6 on Risperidone Metabolism: Pharmacokinetic and Pharmacodynamic Study in a Healthy South Indian Population. Human Psychopharmacology: Clinical and Experimental. 2026;41(3). doi:10.1002/hup.70044
BibTeX
@article{Narayanan2026,
author = {Narayanan, Ramanujam and Rahman, Habibur and Palanisamy, Susipriya and Ranjithkumar, R and Muthusamy, Sivaselvakumar},
title = {Genetic Influence of CYP2D6 on Risperidone Metabolism: Pharmacokinetic and Pharmacodynamic Study in a Healthy South Indian Population},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2026},
volume = {41},
number = {3},
doi = {10.1002/hup.70044}
}
EUVIMED